Wallace L M Alward1,2, Carly van der Heide1,2, Cheryl L Khanna3, Ben R Roos1,2, Sobha Sivaprasad4,5, Jason Kam6, Robert Ritch7, Andrew Lotery8, Robert P Igo9, Jessica N Cooke Bailey9,10, Edwin M Stone1,2, Todd E Scheetz1,2, Young H Kwon1,2, Louis R Pasquale11, Janey L Wiggs11, John H Fingert1,2. 1. Department of Ophthalmology and Visual Sciences, Carver College of Medicine, University of Iowa, Iowa City. 2. Institute for Vision Research, University of Iowa, Iowa City. 3. Department of Ophthalmology, Mayo Clinic, Rochester, Minnesota. 4. Moorfields Eye Hospital, London, England. 5. Kings College Hospital, London, England. 6. Kaiser Permanente, Seattle, Washington. 7. Einhorn Clinical Research Center, New York Eye and Ear Infirmary of Mount Sinai, New York. 8. Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, Southampton, England. 9. Department of Population and Quantitative Health Sciences, Case Western Reserve University School of Medicine, Cleveland, Ohio. 10. Institute for Computational Biology, Case Western Reserve University School of Medicine, Cleveland, Ohio. 11. Massachusetts Eye and Ear Infirmary, Harvard University, Boston.
Abstract
Importance: Mutations in the myocilin (MYOC) gene are the most common molecularly defined cause of primary open-angle glaucoma that typically occurs in patients with high intraocular pressures (IOP). One MYOC mutation, p.Gln368Ter, has been associated with as many as 1.6% of primary open-angle glaucoma cases that had a mean maximum recorded IOP of 30 mm Hg. However, to our knowledge, the role of the p.Gln368Ter mutation in patients with normal-tension glaucoma (NTG) with an IOP of 21 mm Hg or lower has not been investigated. Objective: To evaluate the role of the p.Gln368Ter MYOC mutation in patients with NTG. Design, Setting, and Participants: In this case-control study of the prevalence of the p.Gln368Ter mutation in patients with NTG, cohort 1 was composed of 772 patients with NTG and 2152 controls from the United States (Iowa, Minnesota, and New York) and England and cohort 2 was composed of 561 patients with NTG and 2606 controls from the Massachusetts Eye and Ear Infirmary and the NEIGHBORHOOD consortium. Genotyping was conducted using real-time polymerase chain reaction that was confirmed with Sanger sequencing, the imputation of genome-wide association study data, or an analysis of whole-exome sequence data. Data analysis occurred between April 2007 and April 2018. Main Outcomes and Measures: Comparison of the frequency of the p.Gln368Ter MYOC mutation between NTG cases and controls with the Fisher exact test. Results: Of 6091 total participants, 3346 (54.9%) were women and 5799 (95.2%) were white. We detected the p.Gln368Ter mutation in 7 of 772 patients with NTG (0.91%) and 7 of 2152 controls (0.33%) in cohort 1 (P = .03). In cohort 2, we detected the p.Gln368Ter mutation in 4 of 561 patients with NTG (0.71%) and 10 of 2606 controls (0.38%; P = .15). When the cohorts were analyzed as a group, the p.Gln368Ter mutation was associated with NTG (odds ratio, 2.3; 95% CI, 0.98-5.3; P = .04). Conclusions and Relevance: In cohorts 1 and 2, the p.Gln368Ter mutation in MYOC was found in patients with IOPs that were 21 mm Hg or lower (NTG), although at a frequency that is lower than previously detected in patients with higher IOP. These data suggest that the p.Gln368Ter mutation may be associated with glaucoma in patients with normal IOPs as well as in patients with IOPs that are greater than 21 mm Hg.
Importance: Mutations in the myocilin (MYOC) gene are the most common molecularly defined cause of primary open-angle glaucoma that typically occurs in patients with high intraocular pressures (IOP). One MYOC mutation, p.Gln368Ter, has been associated with as many as 1.6% of primary open-angle glaucoma cases that had a mean maximum recorded IOP of 30 mm Hg. However, to our knowledge, the role of the p.Gln368Ter mutation in patients with normal-tension glaucoma (NTG) with an IOP of 21 mm Hg or lower has not been investigated. Objective: To evaluate the role of the p.Gln368TerMYOC mutation in patients with NTG. Design, Setting, and Participants: In this case-control study of the prevalence of the p.Gln368Ter mutation in patients with NTG, cohort 1 was composed of 772 patients with NTG and 2152 controls from the United States (Iowa, Minnesota, and New York) and England and cohort 2 was composed of 561 patients with NTG and 2606 controls from the Massachusetts Eye and Ear Infirmary and the NEIGHBORHOOD consortium. Genotyping was conducted using real-time polymerase chain reaction that was confirmed with Sanger sequencing, the imputation of genome-wide association study data, or an analysis of whole-exome sequence data. Data analysis occurred between April 2007 and April 2018. Main Outcomes and Measures: Comparison of the frequency of the p.Gln368TerMYOC mutation between NTG cases and controls with the Fisher exact test. Results: Of 6091 total participants, 3346 (54.9%) were women and 5799 (95.2%) were white. We detected the p.Gln368Ter mutation in 7 of 772 patients with NTG (0.91%) and 7 of 2152 controls (0.33%) in cohort 1 (P = .03). In cohort 2, we detected the p.Gln368Ter mutation in 4 of 561 patients with NTG (0.71%) and 10 of 2606 controls (0.38%; P = .15). When the cohorts were analyzed as a group, the p.Gln368Ter mutation was associated with NTG (odds ratio, 2.3; 95% CI, 0.98-5.3; P = .04). Conclusions and Relevance: In cohorts 1 and 2, the p.Gln368Ter mutation in MYOC was found in patients with IOPs that were 21 mm Hg or lower (NTG), although at a frequency that is lower than previously detected in patients with higher IOP. These data suggest that the p.Gln368Ter mutation may be associated with glaucoma in patients with normal IOPs as well as in patients with IOPs that are greater than 21 mm Hg.
Authors: Tayebeh Rezaie; Anne Child; Roger Hitchings; Glen Brice; Lauri Miller; Miguel Coca-Prados; Elise Héon; Theodore Krupin; Robert Ritch; Donald Kreutzer; R Pitts Crick; Mansoor Sarfarazi Journal: Science Date: 2002-02-08 Impact factor: 47.728
Authors: Janey L Wiggs; Michael A Hauser; Wael Abdrabou; Robert Rand Allingham; Donald L Budenz; Elizabeth Delbono; David S Friedman; Jae H Kang; Douglas Gaasterland; Terry Gaasterland; Richard K Lee; Paul R Lichter; Stephanie Loomis; Yutao Liu; Cathy McCarty; Felipe A Medeiros; Sayoko E Moroi; Lana M Olson; Anthony Realini; Julia E Richards; Frank W Rozsa; Joel S Schuman; Kuldev Singh; Joshua D Stein; Douglas Vollrath; Robert N Weinreb; Gadi Wollstein; Brian L Yaspan; Sachiko Yoneyama; Don Zack; Kang Zhang; Margaret Pericak-Vance; Louis R Pasquale; Jonathan L Haines Journal: J Glaucoma Date: 2013-09 Impact factor: 2.503
Authors: J E Craig; P N Baird; D L Healey; A I McNaught; P J McCartney; J L Rait; J L Dickinson; L Roe; J H Fingert; E M Stone; D A Mackey Journal: Ophthalmology Date: 2001-09 Impact factor: 12.079
Authors: E M Stone; J H Fingert; W L Alward; T D Nguyen; J R Polansky; S L Sunden; D Nishimura; A F Clark; A Nystuen; B E Nichols; D A Mackey; R Ritch; J W Kalenak; E R Craven; V C Sheffield Journal: Science Date: 1997-01-31 Impact factor: 47.728
Authors: W L Alward; J H Fingert; M A Coote; A T Johnson; S F Lerner; D Junqua; F J Durcan; P J McCartney; D A Mackey; V C Sheffield; E M Stone Journal: N Engl J Med Date: 1998-04-09 Impact factor: 91.245
Authors: Emmanuelle Souzeau; Kathryn P Burdon; Andrew Dubowsky; Scott Grist; Bronwyn Usher; Jude T Fitzgerald; April Crawford; Alex W Hewitt; Ivan Goldberg; Richard A Mills; Jonathan B Ruddle; John Landers; David A Mackey; Jamie E Craig Journal: Ophthalmology Date: 2013-02-28 Impact factor: 12.079
Authors: Wallace L M Alward; Young H Kwon; Cheryl L Khanna; A Tim Johnson; Sohan S Hayreh; M Bridget Zimmerman; Joanna Narkiewicz; Jeaneen L Andorf; Paula A Moore; John H Fingert; Val C Sheffield; Edwin M Stone Journal: Arch Ophthalmol Date: 2002-09
Authors: Edwin M Stone; Jeaneen L Andorf; S Scott Whitmore; Adam P DeLuca; Joseph C Giacalone; Luan M Streb; Terry A Braun; Robert F Mullins; Todd E Scheetz; Val C Sheffield; Budd A Tucker Journal: Ophthalmology Date: 2017-05-27 Impact factor: 12.079
Authors: Veronica Mendoza-Reinoso; Teja S Patil; Maria L Guevara-Fujita; Silvia Fernández; Enrique Vargas; Wilder Castillo-Herrera; Rodolfo Perez-Grossmann; Frank Lizaraso-Caparó; Julia E Richards; Ricardo Fujita Journal: Mol Vis Date: 2012-08-08 Impact factor: 2.367
Authors: Nazlee Zebardast; Sayuri Sekimitsu; Jiali Wang; Tobias Elze; Puya Gharahkhani; Brian S Cole; Michael M Lin; Ayellet V Segrè; Janey L Wiggs Journal: Ophthalmology Date: 2021-03-10 Impact factor: 14.277
Authors: Elin Holm; Malan Holm; Kaj Vilhelmsen; Gudrid Andorsdottir; Henrik Vorum; Allie Simpson; Benjamin R Roos; John H Fingert; Thomas Rosenberg Journal: J Glaucoma Date: 2022-02-01 Impact factor: 2.290